Allergy Asthma Immunol Res.  2011 Jan;3(1):34-38. 10.4168/aair.2011.3.1.34.

The Financial Burden of Asthma: A Nationwide Comprehensive Survey Conducted in the Republic of Korea

• Kim CY
• Park HW
• Ko SK
• Chang SI
• Moon HB
• Kim YY
• Cho SH

• KMID: 2260375
• DOI: http://doi.org/10.4168/aair.2011.3.1.34

Abstract

PURPOSE
Asthma-related morbidity and mortality are increasing, and the financial burden imposed by this condition will substantially increase. Nevertheless, little information is available regarding the nature and magnitude of the burden due to asthma at the national level. This study was conducted to characterize the financial burden imposed by asthma in the Republic of Korea at the national level.
METHODS
The overall prevalence of asthma and the costs of related medical services were determined using data from the National Health Insurance Corporation, which is responsible for the National Health Insurance scheme. Indirect costs, including expenditures on complementary and alternative medicines, and the economic impact of an impaired quality of life (intangible costs) were estimated by surveying 660 asthmatics, and these estimates were transformed to the national level using the prevalence of asthma.
RESULTS
The prevalence of asthma and total costs related to the disease in 2004 were 4.19% and $2.04 billion, respectively. Direct costs and indirect costs contributed equally to total costs (46.9% and 53.1%, respectively). However, when intangible costs were included, total costs rose to $4.11 billion, which was equivalent to 0.44% of the national gross domestic product in 2004.
CONCLUSIONS
The results provide evidence that asthma is a major health cost factor in the Republic of Korea and that intangible costs associated with asthma are significant cost drivers.

Keyword

Asthma; prevalence; cost-of-illness; direct costs; indirect costs; quality of life

MeSH Terms

Asthma
Gross Domestic Product
Health Care Costs
Health Expenditures
National Health Programs
Prevalence
Quality of Life
Republic of Korea

Reference

1. Mellis CM, Peat JK, Bauman AE, Woolcock AJ. The cost of asthma in New South Wales. Med J Aust. 1991. 155:522–528.

2. Krahn MD, Berka C, Langlois P, Detsky AS. Direct and indirect costs of asthma in Canada, 1990. CMAJ. 1996. 154:821–831.

3. Szucs TD, Anderhub H, Rutishauser M. The economic burden of asthma: direct and indirect costs in Switzerland. Eur Respir J. 1999. 13:281–286.

4. Chew FT, Goh DY, Lee BW. The economic cost of asthma in Singapore. Aust N Z J Med. 1999. 29:228–233.

5. Weiss KB, Sullivan SD, Lyttle CS. Trends in the cost of illness for asthma in the United States, 1985-1994. J Allergy Clin Immunol. 2000. 106:493–499.

6. Gupta R, Sheikh A, Strachan DP, Anderson HR. Burden of allergic disease in the UK: secondary analyses of national databases. Clin Exp Allergy. 2004. 34:520–526.

7. Poulos LM, Toelle BG, Marks GB. The burden of asthma in children: an Australian perspective. Paediatr Respir Rev. 2005. 6:20–27.

8. Barnes PJ, Jonsson B, Klim JB. The costs of asthma. Eur Respir J. 1996. 9:636–642.

9. Expert panel report 3: guidelines for the diagnosis and management of asthma [Internet]. National Heart, Lung, and Blood Institute. 2007. updated 2007 Aug 28; cited 2010 Feb 1. Bethesda (MD): U.S. Dept. of Health and Human Services, National Institutes of Health, National Heart, Lung, and Blood Institute;Available from: http://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf.

10. British Thoracic Society Scottish Intercollegiate Guidelines Network. British Guideline on the Management of Asthma. Thorax. 2008. 63:Suppl 4. iv1–iv121.

11. Bielory L. Complementary and alternative interventions in asthma, allergy, and immunology. Ann Allergy Asthma Immunol. 2004. 93:S45–S54.

12. Schäfer T. Epidemiology of complementary alternative medicine for asthma and allergy in Europe and Germany. Ann Allergy Asthma Immunol. 2004. 93:S5–S10.

13. Ernst E. Complementary therapies for asthma: what patients use. J Asthma. 1998. 35:667–671.

14. Senna G, Passalacqua G, Crivellaro M, Bonadonna P, Gani F, Dorizzi R, Dama A, Canonica GW, Lombardi C. Unconventional medicine: a risk of undertreatment of allergic patients. Allergy. 1999. 54:1117–1119.

15. Kwon S. Payment system reform for health care providers in Korea. Health Policy Plan. 2003. 18:84–92.

16. International classification of diseases [Internet]. World Health Organization. cited 2010 Feb 1. Available from: http://www.who.int/classifications/icd/en/.

17. Global strategy for asthma management and prevention [Internet]. Global Initiative for Asthma. GINA Workshop Report. cited 2010 Feb 1. Available from: http://www.ginasthma.com.

18. Park JW, Cho YS, Lee SY, Nahm DH, Kim YK, Kim DK, Sohn JW, Park JK, Jee YK, Cho YJ, Yoon HJ, Kim MK, Park HS, Choi BW, Choi IS, Park CS, Min KU, Moon HB, Park SH, Lee YK, Kim NS, Hong CS. Multi-center study for the utilization of quality of life questionnaire for adult Korean asthmatics (QLQAKA). J Asthma Allergy Clin Immunol. 2000. 20:467–480.

19. Johannesson M, Jönsson B, Borgquist L. Willingness to pay for antihypertensive therapy--results of a Swedish pilot study. J Health Econ. 1991. 10:461–473.

20. The World Factbook 2010 - Korea, South [Internet]. Central Intelligence Agency. cited 2010 Sep 17. Available from: https://www.cia.gov/library/publications/the-world-factbook/geos/ks.html.

21. Kim YK, Kim SH, Tak YJ, Jee YK, Lee BJ, Park HW, Jung JW, Bahn JW, Chang YS, Choi DC, Chang SI, Min KU, Kim YY, Cho SH. High prevalence of current asthma and active smoking effect among the elderly. Clin Exp Allergy. 2002. 32:1706–1712.

22. Peabody JW, Lee SW, Bickel SR. Health for all in the Republic of Korea: one country's experience with implementing universal health care. Health Policy. 1995. 31:29–42.

23. Smith DH, Malone DC, Lawson KA, Okamoto LJ, Battista C, Saunders WB. A national estimate of the economic costs of asthma. Am J Respir Crit Care Med. 1997. 156:787–793.

24. Schäfer T, Riehle A, Wichmann HE, Ring J. Alternative medicine in allergies - prevalence, patterns of use, and costs. Allergy. 2002. 57:694–700.

25. Blumenschein K, Johannesson M. Relationship between quality of life instruments, health state utilities, and willingness to pay in patients with asthma. Ann Allergy Asthma Immunol. 1998. 80:189–194.

26. Lundberg L, Johannesson M, Silverdahl M, Hermansson C, Lindberg M. Quality of life, health-state utilities and willingness to pay in patients with psoriasis and atopic eczema. Br J Dermatol. 1999. 141:1067–1075.

27. Zillich AJ, Blumenschein K, Johannesson M, Freeman P. Assessment of the relationship between measures of disease severity, quality of life, and willingness to pay in asthma. Pharmacoeconomics. 2002. 20:257–265.